Cas9 Stable Cell Line - ID8

The Cas9 Stable Cell Line - ID8 is a genetically engineered mouse ovarian cancer cell line integrating the CRISPR-Cas9 system for targeted genome editing. Derived from the original ID8 cells (a well-established ovarian cancer research model), this stable cell line constitutively expresses the Cas9 nuclease protein. The ID8 cell line itself originates from C57BL/6 mouse ovarian surface epithelial cells, transformed with the SV40 large T antigen to acquire immunomodulatory activity, making it ideal for studying tumor microenvironment interactions. The integration of Cas9 allows researchers to bypass transient transfection steps, ensuring stable and efficient gene editing across various experiments.

This genetically engineered cell line significantly accelerates the application of functional genomics and drug development. Researchers use Cas9-ID8 cells for high-throughput CRISPR screening to identify ovarian cancer-specific oncogenes, tumor suppressor genes, and drug resistance mechanisms. Stable Cas9 expression enables the rapid construction of gene knockout/knock-in models, allowing for the validation of therapeutic targets such as PARP inhibitor responses or immunotherapy responses. Furthermore, these cells facilitate in vivo studies: when implanted into syngeneic mice, they form tumors that retain the CRISPR-editable properties, allowing for the study of the tumor microenvironment and gene function during metastasis. Beyond basic research, Cas9-ID8 simplifies preclinical testing and biomarker discovery for combination therapies, providing a versatile tool for developing personalized treatment strategies targeting the heterogeneity of ovarian cancer.